Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Paratek highlights omadacycline efficacy
July 2018
SHARING OPTIONS:

BOSTON—Biopharmaceutical company Paratek Pharmaceuticals Inc. recently shared a new analysis of its Phase 3 OPTIC study of omadacycline vs. moxifloxacin in treating community-acquired bacterial pneumonia (CABP), with the results presented at this year’s American Thoracic Society 2018 International Conference. Efficacy results for the study were presented by measurements of disease severity, and similar high response rates were seen for the early clinical response and post-therapy evaluation (also known as test-of-cure) endpoints in both treatment groups regardless of disease severity.
 
“This analysis underscores that across the range of disease severity studied, omadacycline demonstrated high rates of clinical success at the early response timepoint in hospitalized CABP patients. The implications for clinical practice are that achieving clinical success at an early timepoint could potentially result in transition from intravenous to oral omadacycline, allowing for hospital discharge,” said Paul McGovern, Paratek’s vice president of clinical affairs.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.